Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENT-01 in Parkinson's Disease Dementia
NCT03938922Phase 1Withdrawn
- Sponsor
- Enterin Inc.
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Multivalent & Scaffold-Based Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of squalamine in Parkinson's disease dementia (PDD), sponsored by Enterin Inc. Primary endpoint: Cognition Improvement by Dementia Severity Rating Scale at 10 weeks. Planned start Mar 2024; status: withdrawn.
02
Drugs
squalamine
03
Conditions
Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT03938922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938922.